fashion -WSS

fashion

author：comprehensive 2025-09-29 06:48:03 - browse：767

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： FDA's Pazdur wants cancer trials to range beyond China alone

knowledge

Wikipedia

focus

WSS

HCA discloses massive data breach affecting 11 million patients

Bulgari apologizes to China for listing Taiwan as a country after online backlash

A new study sees potential in DNA sequencing of infants

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

FDA's Pazdur wants cancer trials to range beyond China alone

leisure time

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

George Santos makes 1st court appearance after pleading not guilty to 13 counts

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

Affirmative action in medical school literally saved lives

Let's speed up science by embracing open access publishing

Bright Health sells Medicare Advantage business to Molina

California’s proposed $25 per hour health care minimum wage

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Kaiser's Risant Health gobbled up Geisinger. Who is next?

In age of alternative facts, a scholarly course on calling out crap

Study: Pain burden is higher in Black NFL players than white ones

knowledge

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

New research casts further doubt on a common procedure used with IVF

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Retired US general questions alleged Putin, Prigozhin meeting

Change Healthcare can notify patients about the breach, HHS says

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

knowledge

Wikipedia

focus

Wikipedia